Boan Biotech Explains Trading Surge as Share Transfer and Wins Bolivia Nod for Denosumab Biosimilar
I'm PortAI, I can summarize articles.
Shandong Boan Biotechnology Company (HK:6955) clarified that the recent surge in trading volume of its H shares is due to on-market transfers related to exchangeable preference shares from its controlling shareholder, Luye Pharma Group. The company confirmed no undisclosed corporate developments or ongoing negotiations. Additionally, Boan's denosumab biosimilar injection BA6101 has received marketing authorization in Bolivia, supporting its strategy to expand internationally. The product is also under review in the UK, with plans for further filings in Europe, the US, and Japan, enhancing its global market presence.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments